Tesamorelin

A GHRH analog with an FDA-approved indication (marketed as Egrifta) for reducing excess visceral fat in HIV-associated lipodystrophy — a catalog item with an approved-drug analog worth flagging for legal review. Stimulates endogenous GH release from the pituitary, which in turn drives IGF-1 production.

Visceral (abdominal) fat reduction specifically — tesamorelin's research base is unusually focused on this outcome compared to other GH secretagogues.

Lyophilized. Reconstitute with bacteriostatic water per the general reference below.

General reconstitution & storage reference for lyophilized peptides:

1. 1Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water — the preservative meaningfully extends usable shelf life.
2. 2In bacteriostatic water, refrigerate at 2–8°C, typically usable for ~28–30 days. In plain sterile water (no preservative): 7–14 days.
3. 3Lyophilized (unmixed) vials are stable at refrigerated or, for some peptides, frozen temperatures for extended periods prior to reconstitution.
4. 4Avoid repeated freeze-thaw cycles, direct light/UV exposure, and heat — these are the primary drivers of peptide degradation.
5. 5Reconstitute gently: inject the water down the inside wall of the vial and swirl — don't shake, which can denature the peptide structure.

GH-axis cautions apply (glucose/insulin sensitivity monitoring); approved-drug status means off-label/RUO marketing claims should be handled carefully.

• Research literature — Tesamorelin / Egrifta